BACKGROUND: A new challenge stock of the simian immunodeficiency virus SIVmacJ5 has been produced following passage in vivo. METHODS: SIVmacJ5 3/92 (J5M), was passaged serially through cynomolgus macaques (Macaca fascicularis) by intravenous inoculation of infected spleen cells isolated and prepared 14 days post-infection. Two challenge stocks, SIVmacJ5 S61MLN and SIVmacJ5 S62spl, were prepared by culture of lymphoid tissue ex vivo. RESULTS: These virus stocks appeared better adapted for replication in M. fascicularis as demonstrated by a greater persistence of recoverable live virus from the periphery and increased pathology in lymphoid tissues 20 weeks post-challenge as detected by immunohistochemistry. Sequence analysis of the envelope gene from these stocks did not identify marked diversification of sequence as a result of this procedure. CONCLUSIONS: These stocks display more robust peripheral persistence and tissue pathology in cynomolgus macaques and should prove valuable analysing recombinant vaccines based upon SIVmacJ5 transgenes.
BACKGROUND: A new challenge stock of the simian immunodeficiency virus SIVmacJ5 has been produced following passage in vivo. METHODS: SIVmacJ5 3/92 (J5M), was passaged serially through cynomolgus macaques (Macaca fascicularis) by intravenous inoculation of infected spleen cells isolated and prepared 14 days post-infection. Two challenge stocks, SIVmacJ5 S61MLN and SIVmacJ5 S62spl, were prepared by culture of lymphoid tissue ex vivo. RESULTS: These virus stocks appeared better adapted for replication in M. fascicularis as demonstrated by a greater persistence of recoverable live virus from the periphery and increased pathology in lymphoid tissues 20 weeks post-challenge as detected by immunohistochemistry. Sequence analysis of the envelope gene from these stocks did not identify marked diversification of sequence as a result of this procedure. CONCLUSIONS: These stocks display more robust peripheral persistence and tissue pathology in cynomolgus macaques and should prove valuable analysing recombinant vaccines based upon SIVmacJ5 transgenes.
Authors: Bo Li; Neil Berry; Claire Ham; Deborah Ferguson; Deborah Smith; Joanna Hall; Mark Page; Ruby Quartey-Papafio; William Elsley; Mark Robinson; Neil Almond; Richard Stebbings Journal: Retrovirology Date: 2011-02-03 Impact factor: 4.602
Authors: Neil Almond; Neil Berry; Richard Stebbings; Mark Preston; Claire Ham; Mark Page; Debbie Ferguson; Nicola Rose; Bo Li; Edward T Mee; Mark Hassall; Christiane Stahl-Hennig; Takis Athanasopoulos; Timos Papagatsias; Shanthi Herath; Adel Benlahrech; George Dickson; Andrea Meiser; Steven Patterson Journal: J Virol Date: 2019-10-15 Impact factor: 5.103
Authors: Deborah Ferguson; Giada Mattiuzzo; Claire Ham; Richard Stebbings; Bo Li; Nicola J Rose; Edward T Mee; Deborah Smith; Mark Page; Martin P Cranage; Neil Almond; Greg J Towers; Neil J Berry Journal: PLoS One Date: 2014-08-27 Impact factor: 3.240